Compare Advanced Micro Devices (AMD) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advanced Micro Devices vs BioNTech SE - ADR — how do they compare? Advanced Micro Devices trades at $543.66 (market cap $909.70B), while BioNTech SE - ADR trades at $91.14 (market cap $23.14B). The key difference: Advanced Micro Devices is far larger — about 39.3× BioNTech SE - ADR's market cap, and Advanced Micro Devices is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AMD | BNTX | |
|---|---|---|
Market Cap | $909.70B | $23.14B |
Sector | Technology | Health |
52-Week High | $580.91 | $119.34 |
52-Week Low | $146.24 | $83.89 |
Enterprise Value | $901.22B | $6.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today, approaching its 52-week high amid strong AI-driven momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth, reaching $34.64B in 2025. Analyst sentiment remains overwhelmingly positive with a 71.43% buy rating, though valuation metrics like a P/E of 185.96 indicate premium pricing. Cash flow from operations surged to $7.71B in 2025, supporting aggressive investment in AI infrastructure.
Outlook: AMD is well-positioned to capitalize on AI and data center demand, but high valuation and intense competition pose risks. Investors should weigh growth potential against premium multiples, with the consensus price target of $508.24 suggesting near-term caution despite long-term optimism.
BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.
The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
